HPS Pharmacies wish to give notice that Viatris, in consultation with the Therapeutic Goods Administration (TGA), has initiated a product defect correction for Midazolam Alphapharm injection (now branded as Midazolam Viatris injection) as follows:
Midazolam 50 mg/10 mL
The only batch affected by this product defect correction is: F3138F02 (Exp 12/24)
This product defect correction is being undertaken due to the detection of a single ampoule of Urapidil Stragen 50mg/10ml in this batch of midazolam ampoules.
Please inspect your stock and quarantine any defect stock. If HPS Pharmacies provide imprest management services to your facility, an HPS representative will inspect all stock stored in the designated imprest areas at the earliest opportunity. All affected products will be quarantined for return to the supplier, and HPS Pharmacies will arrange for replacement stock as soon as possible. An HPS Pharmacies staff member will contact senior medical and nursing staff if there is an immediate impact to your facility.
Only cartons of Midazolam Alphapharm 50 mg/10 mL Injection that contain an ampoule of Urapidil Stragen are impacted by this event. If no Urapidil ampoules are contained, use of Midazolam Alphapharm from batch F3138F02 may continue.
Retain this notice in a prominent position, including in other related business units for one month. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Viatris on 1800 274 276 or your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates